Lyell Immunopharma (LYEL) Balance Sheet: Assets & Liabilities

Lyell Immunopharma (LYEL) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Lyell Immunopharma reported total assets of $340.05M and total liabilities of $91.85M. Shareholders' equity was $248.20M, down 35.2% from $382.82M a year earlier. Total debt stood at $50.99M against $247.22M in cash and short-term investments, a net cash position of $196.23M. That puts debt-to-equity at 0.21, compared with 0.15 a year earlier.

Lyell Immunopharma Balance Sheet Analysis

Values in billions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Lyell Immunopharma, Inc. (LYEL) - Annual data in billions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	0.06	0.11	0.15	0.12	0.29	0.14	0.10
Short-Term Investments	0.19	0.26	0.40	0.52	0.32	0.47	0.34
Cash & Short-Term Investments	0.25	0.37	0.55	0.64	0.61	0.61	0.44
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.01	0.01	0.01	0.01	0.01	0.00	0.00
Total Current Assets	0.26	0.38	0.55	0.65	0.63	0.62	0.44
Non-Current Assets
Property, Plant & Equipment (Net)	0.05	0.07	0.14	0.17	0.17	0.12	0.04
Long-Term Investments	0.02	0.03	0.05	0.12	0.33	0.16	0.07
Other Non-Current Assets	0.01	0.01	0.00	0.00	0.00	0.00	0.00
Total Non-Current Assets	0.08	0.11	0.20	0.29	0.50	0.29	0.12
Total Assets	0.34	0.49	0.75	0.94	1.13	0.91	0.56
Current Liabilities
Accounts Payable	0.00	0.01	0.00	0.00	0.00	0.01	0.00
Short-Term Debt	0.01	0.01	0.01	0.00	0.00	0.00	0.00
Accrued Liabilities	0.05	0.01	0.03	0.01	0.03	0.02	-
Deferred Revenue	0.00	0.00	0.00	0.00	0.00	0.01	0.00
Other Current Liabilities	0.00	0.00	0.00	0.01	0.04	0.03	0.01
Total Current Liabilities	0.05	0.05	0.03	0.04	0.05	0.05	0.02
Non-Current Liabilities
Long-Term Debt	0.04	0.05	0.06	0.06	0.07	0.05	0.03
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Non-Current Liabilities	0.04	0.05	0.06	0.07	0.15	0.14	0.13
Total Liabilities	0.09	0.11	0.10	0.10	0.20	0.19	0.15
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-1.62	-1.35	-1.00	-0.77	-0.58	-0.33	-0.13
Accumulated Other Comprehensive Income	0.00	0.00	0.00	-0.01	0.00	0.00	0.00
Additional Paid-in Capital	1.87	1.73	1.66	1.61	1.52	0.04	0.02
Shares Outstanding	0.02	0.01	0.01	0.01	0.01	-	-
Total Stockholders' Equity	0.25	0.38	0.65	0.83	0.93	0.72	0.41
Total Liabilities & Equity	0.34	0.49	0.75	0.94	1.13	0.91	0.56

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Lyell Immunopharma Balance Sheet

How much debt does Lyell Immunopharma have?

Lyell Immunopharma had total debt of $50.99M as of Dec 31, 2025, against $247.22M in cash and short-term investments. Its debt-to-equity ratio was 0.21. Total debt was $58.97M a year earlier.

What are Lyell Immunopharma's total assets?

Lyell Immunopharma reported total assets of $340.05M as of Dec 31, 2025, down 30.7% from $490.86M a year earlier. Total liabilities were $91.85M.

What is Lyell Immunopharma's shareholders' equity?

Lyell Immunopharma's shareholders' equity was $248.20M as of Dec 31, 2025, or about $11.68 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition